(Bird chirping). No one can answer that question. It's

New Post Public Reply Private Reply Replies (1) Message Board
LveGun-TakeCannoli ClosetInvestor #27910
488
Quote:
(Bird chirping). No one can answer that question.


It's pretty simple. They need to prove EFFICACY & SAFETY. Everyone seems to ignore the fact that many, many people are recovering on their own. That's much less the case once you are on a respirator where the death rate is as high as 80%.

But the fact remains, you need to show STATISTICAL RELEVANCE that exceeds the chance people are just improving on their own. It's the same with Hydroxychloroquine. You need to test in a controlled fashion.

All these people whining about patients in a severe condition being allowed to die because they're in the placebo arm is pure hogwash. There are procedures in place to unblind and move to the control group if necessary.

You should all be ecstatic that the FDA wants proof. Otherwise, there would be a lot of drugs/treatments out there, unproven and detracting from leronlimab's results. It's an extremely short trial and interim analysis is even shorter.

What you really should be concerned about is the company sourcing funds to support a huge spike in expenses and it's about to get much, much worse. I hope a govt grant is provided. But I think it's a very small chance. If there were ever a case for it, this would be it.

Now, what happened to the emergency FDA approval that NP was brandishing last week?

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Bunge Limited Faces Market Pressures with Stock Drop

Updated Category News Views 262

Bunge Limited Faces Market Pressures as Stock Prices Decline In a year characterized by considerable market fluctuations, Bunge Limited (NYSE: BG) has seen its stock reach a concerning 52-week low of $77.52. With an attractive price-to-earnings (P/E) ratio of 9.7 and a commendable dividend yield of 3.48%, Bunge has consistently paid dividends for an impressive 24 years,...

Continue Reading
Key Market Events to Monitor This Coming Week

Updated Category News Views 511

Upcoming Market Highlights to Observe As we look ahead, several significant events are poised to influence market dynamics. As corporate earnings season blossoms, attention will focus on major players in tech, finance and energy sectors. Global leaders are gathering to discuss critical economic issues, all while fluctuating oil prices add to the tension. Let's explore...

Continue Reading
Touchmark Bancshares: OCC Agreement Axed, What’s Next?

Updated Category News Views 159

Touchmark Bancshares, Inc. just cut ties with the Office of the Comptroller of the Currency (OCC) on February 17, 2026, after a lengthy 22-month oversight period. This enforcement action was slapped on them back in April 2024, and it seemed like a cloud hanging over their heads for ages. Traders were watching closely—this termination isn’t just a footnote; it speaks...

Continue Reading
Bybit Unveils Inclusive WSOT 2025 with Massive Prize Pool

Updated Category News Views 531

Bybit Kicks Off an Innovative WSOT 2025 Bybit, a leading player in the cryptocurrency exchange arena, is taking bold steps to redefine the World Series of Trading (WSOT) in its upcoming 2025 edition. Known for hosting the longest-running crypto trading competition globally, Bybit is set to catapult this event into a new era, offering a staggering 10 million USDT prize...

Continue Reading
Brookfield Corporation Announces Q2 2025 Earnings Call Details

Updated Category News Views 396

Brookfield Corporation to Host Second Quarter 2025 Results Conference Call BROOKFIELD, NEWS — Brookfield Corporation (NYSE: BN) will host its second quarter 2025 conference call and webcast on Thursday, August 7, 2025, at 10:00 AM (ET). Key Information and Joining Details Results from the financial quarter will be released that morning around 7:00 AM (ET) and will be...

Continue Reading